RAD51 and plasma cell myeloma: These data are consistent with our previous data demonstrating that inhibition of RAD51 in cancer cells [multiple myeloma (MM) and esophageal adenocarcinoma (EAC)], by transgenic and/or chemical modifications, inhibits HR and genomic instability [9,10,34] and etoposide-induced DNA damage [35].